Qureight Board of Directors elects Dr. Neil Johnston to the Board as Non-Executive Chair, Dr Claus Torp Jensen to step down from the Board and is appointed Chair of the Scientific Advisory Committee.
Qureight Ltd, a Core Imaging Platform based in Cambridge UK today announced changes to the company’s Board of Directors. Dr. Neil Johnston has been elected as Non-Executive Chair. The previous Chair Dr Claus Torp Jensen has stepped down from the Board and is appointed Chair of the Scientific Advisory Committee.
Dr Johnston said: “I am delighted and honoured to join the Board of Qureight as Non-Executive Chair. I have been extremely impressed with the progress made to date and truly believe that Qureight is one of the most exciting companies in its field. I am looking forward to working with the Board, the investors and with Muhunthan and his team to drive even greater success in future”.
Dr Torp Jensen said: “I have had the privilege of Chairing the Board of Qureight for the past two years, and watched as the company has grown be to a major presence in the clinical trial space. From the earliest stage, product and technology strategy have been a key part of boardroom discussions. I am thrilled to continue my engagement as Chair of the Scientific Advisory Committee and to support Muhunthan and the leadership team as they scale the company”.
Qureight's CEO Dr. Muhunthan Thillai said: "I am really excited to welcome Neil as Non-Executive Chair to our Board of Directors. He has significant experience in finance and business strategy having spent 16 years at Novartis in a range of senior leadership roles including as Global Head of Business Development and Licencing. His background and experience will be crucial as we scale our AI product strategy this year and start work on a series of late stage clinical trials across multiple lung and heart diseases. I would also like to acknowledge the work done by Claus over the past two years. He helped define our technology roadmap and navigate through our successful series A fundraise. I am delighted that he is staying on to Chair our Scientific Advisory Committee and want to thank him for both his support and continued friendship."
About Dr. Johnston
Dr. Neil Johnston has a global track record in biopharma finance and business development. He originally studied as a scientist and gained a PhD in Molecular Biology before qualifying as a Chartered Accountant. After becoming CFO of Pharmagene plc where he played a key role in the London main market IPO raising £40m, he joined Medical Solutions plc, initially as CFO and then as CEO. He later moved to Novartis where he held a series of senior leadership positions over 16 years culminating as Global Head of Business Development and Licencing Novartis Pharma/Novartis AG from 2017-2023 and was a member of Novartis Pharma Executive Committee. He is also currently Executive Chair at Yellowstone Biosciences.
About Qureight
Founded in 2018 and headquartered in Cambridge UK, Qureight is a Core Imaging Platform with a focus on drug development for lung and heart diseases. The company deploys its technology on a global scale by integrating into clinical trials with its image based AI products. The cloud-based, vendor-agnostic platform is GDPR, HIPPA and NHS Digital compliant. The platform has ISO13485 and ISO27001 accreditation to interrogate clinical trial data at scale.
Media enquiries:
Amy Thomas
amy@somx.health